Gastric cancer incidence and mortality trends 2007–2016 in three European countries

Diogo Libânio; Jessica R. Rodrigues; Maria J. Bento; Alanna Ebigbo; Helmut Messman; Rob H.A. Verhoeven; Nancy Van Damme; Raf Bisschops; Manon C.W. Spaander; Marío Dinis-Ribeiro

doi:10.1055/a-1673-1118

Endoscopy, Table of Contents

Endoscopy 2022; 54(07): 644-652
DOI: 10.1055/a-1673-1118

Original article

Gastric cancer incidence and mortality trends 2007–2016 in three European countries

Diogo Libânio ‡^*

¹Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal

²MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal

,

Jessica R. Rodrigues‡^*

³Cancer Epidemiology Group, Portuguese Oncology Institute of Porto, Porto, Portugal

⁴Centre of Mathematics (CMAT), University of Minho, Portugal

,

Maria J. Bento

³Cancer Epidemiology Group, Portuguese Oncology Institute of Porto, Porto, Portugal

⁵Department of Population Studies, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal

,

Alanna Ebigbo

⁶(Internal) Medicine III – Gastroenterology, University Hospital of Augsburg, Augsburg, Germany

,

Helmut Messman

⁶(Internal) Medicine III – Gastroenterology, University Hospital of Augsburg, Augsburg, Germany

,

Rob H.A. Verhoeven

⁷Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL) Utrecht, the Netherlands

⁸Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

,

Nancy Van Damme

⁹Belgian Cancer Registry, Brussels, Belgium

,

Raf Bisschops

¹⁰Department of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium

,

Manon C.W. Spaander ^**

¹¹Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands

,

Marío Dinis-Ribeiro^**

¹Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal

²MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal

› Author Affiliations

Abstract

Background Increased awareness of gastric cancer risk, easy access to upper endoscopy, and high definition endoscopes with virtual chromoendoscopy may have led to the increase in early diagnosis of gastric cancer observed in recent years in Europe, which may be associated with improved survival. Currently, no data exist on the impact of early diagnosis on survival at a populational level in Europe. Our aim was to assess gastric cancer incidence, early diagnosis, and survival in northwestern and southern European countries with a low-to-moderate incidence of gastric cancer.

Methods Data on 41 138 gastric cancers diagnosed in 2007–2016 were retrieved from national cancer registries of Belgium, the Netherlands, and northern Portugal. Age-standardized incidence and mortality rates were assessed and expressed per 100 000 person-years. Early diagnosis was defined as T1 tumors. Net survival estimates for 2007–2011 vs. 2012–2016 were compared.

Results Age-standardized incidence and mortality decreased over time in Belgium, northern Portugal, and the Netherlands (relative incidence decrease 8.6 %, 4.5 %, and 46.8 %, respectively; relative mortality decrease 22.0 %, 30.9 %, and 50.0 %, respectively). Early gastric cancer diagnosis increased over time for all countries. Net 1-year survival improved significantly between the two time periods in all countries, and at 5 years in Belgium and Portugal.

Conclusions This is the first study comparing trends (2007–2016) in gastric cancer incidence and mortality in some European countries. We found an increasing proportion of T1 gastric cancers and a decrease in age-standardized mortality over time, supporting the use of secondary prevention strategies.

Full Text

References

References
1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
2 Balakrishnan M, George R, Sharma A. et al. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep 2017; 19: 36
3 International Agency for Research on Cancer. Cancer tomorrow. Lyon: International Agency for Research on Cancer; 2020
4 Arnold M, Abnet CC, Neale RE. et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159: 335-349
5 Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med 2019; 70: 353-367
6 Pech O, May A, Manner H. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660
7 Ding YE, Li Y, He XK. et al. Impact of Barrett’s esophagus surveillance on the prognosis of esophageal adenocarcinoma: a meta-analysis. J Dig Dis 2018; 19: 737-744
8 Codipilly DC, Chandar AK, Singh S. et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology 2018; 154: 2068-2086
9 Kahi CJ, Imperiale TF, Juliar BE. et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7: 770-775
10 Libânio D, Braga V, Ferraz S. et al. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients’ perspectives. Endoscopy 2019; 51: 30-39
11 Dinis-Ribeiro M, Areia M, de Vries AC. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94
12 Areia M, Dinis-Ribeiro M, Rocha Goncalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. Helicobacter 2014; 19: 425-436
13 Areia M, Spaander MC, Kuipers EJ. et al. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018; 6: 192-202
14 World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization; 1992 Available at (Accessed 26.09.2021): https://apps.who.int/iris/handle/10665/37958
15 Cancer incidence in five continents. Waterhouse JAH, Muir CS, Correa P, Powell J. 3. Lyon: IARC; 1976: 456
16 Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890
17 Pohar Perme M, Stare J, Estève J. On estimation in relative survival. Biometrics 2012; 68: 113-120
18 Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-2316
19 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
20 Bisschops R, Areia M, Coron E. et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2016; 48: 843-864
21 Toyoda Y, Tabuchi T, Hama H. et al. Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: stomach, colorectum, lung, breast and cervix. PLoS One 2020; 15: e0244644
22 Kim Y, Jun JK, Choi KS. et al. Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev 2011; 12: 725-730
23 Pimenta-Melo AR, Monteiro-Soares M, Libanio D. et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28: 1041-1049
24 Allemani C, Matsuda T, Di Carlo V. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-1075
25 Karimi P, Islami F, Anandasabapathy S. et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014; 23: 700-713
26 Luo G, Zhang Y, Guo P. et al. Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. Int J Cancer 2017; 141: 1333-1344
27 GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 2020; 5: 42-54
28 Tang CT, Zeng L, Yang J. et al. Analysis of the incidence and survival of gastric cancer based on the Lauren classification: a large population-based study using SEER. Front Oncol 2020; 10: 1212